Study finds sustained-release dexamfetamine is promising for reducing cocaine use
|
|
- Cody Parsons
- 5 years ago
- Views:
Transcription
1 CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study finds sustained-release dexamfetamine is promising for reducing cocaine use 27 April 2016 Depending on the circumstances, the use of street drugs can increase a person s risk for exposure to germs, including bacterial infections and blood-borne viruses such as HIV and hepatitis C virus (HCV). In people with these viruses, exposure to street drugs also contributes to ill health. Therefore, researchers need to find ways to help substance users reduce their exposure to street drugs and, if possible, quit. Heroin and cocaine Several well-designed clinical trials have found that treatment with medically prescribed and supervised heroin can be useful for some people who are heroin-dependent and for whom methadone alone does not work. In these studies, researchers have found that heroin used in such circumstances has resulted in improvements in mental status, physical health and social functioning. However, addiction specialists have found that many heroin-dependent patients are also cocaine dependent. In such cases of dual dependency, doctors have struggled to help patients sustain a decrease in cocaine usage. There have been many clinical trials of medicines to assess their potential for reducing cocaine dependence, but so far there is no therapy that has been licensed for this use. Amphetamine-based therapy Results from clinical trials suggest that some medicines that interact with the chemical messenger dopamine (used by cells in the brain and in other parts of the body to communicate) might be a useful path to pursue in the quest to reduce cocaine use and dependency. Researchers have been studying slow- or sustained-release forms of amphetamines for this purpose. A team of researchers in the Netherlands has been exploring multiple approaches in its quest to help cocaine users reduce their use. In their latest report, published in the Lancet, the researchers analysed findings from a multicentre, randomized, placebo-controlled clinical trial of 12 weeks of daily, supervised, oral sustained-release dexamfetamine (60 mg/day) or placebo. All participants used crack cocaine and also received prescribed heroin and methadone. The researchers found that participants who received sustained-release dexamfetamine used cocaine for significantly fewer days. Side effects were generally temporary and well tolerated, according to the researchers. The study was relatively short and, although no one ceased cocaine consumption, its findings are promising and pave the way for further studies of dexamfetamine by itself and, perhaps in combination with other medicines. Study details A research team in the Netherlands is conducting studies of different interventions to try to help people decrease their use of cocaine. In one of those studies, researchers screened potential volunteers from supervised, heroinassisted treatment programmes in Amsterdam, Rotterdam and The Hague. They recruited 73 people and randomly assigned them to the following groups:
2 sustained-release dexamfetamine 38 people fake dexamfetamine (placebo) 35 people Participants were recruited between August 2014 and February They took dexamfetamine or placebo under the observation of clinic staff. The average profile of participants upon entering the study was as follows: age 49 years 90% men, 10% women years of cocaine use 20 years proportion with a positive urine test for cocaine on the first day of the study 99% number of days in the past month in which cocaine was used 24 days years of heroin use 22 years proportion with heavy alcohol use (five or more drinks daily) for at least one day in the past month 34% number of different anti-addiction treatments that participants had previously tried seven Researchers did not disclose if participants had chronic viral infections such as HIV or HCV. Results Over the course of the study, the average number of (self-reported) days of cocaine use was distributed as follows: dexamfetamine group 45 days placebo group 61 days This difference was statistically significant; that is, not likely due to chance alone. Reduction in cocaine use occurred regardless of the city in which participants lived. Participants who received dexamfetamine were more likely to be abstinent from cocaine for a period of time. The distribution of participants with the longest period of consecutive cocaine abstinence was as follows: dexamfetamine group 25 days placebo group 12 days The proportions of participants who were able to stop taking cocaine for at least 21 days were as follows: dexamfetamine group 29% placebo group 6% All of the above differences were statistically significant. During the final four weeks of the study, researchers instituted twice-weekly urine screening for cocaine. Overall, the findings during this part of the study were broadly similar to those in the rest of the study, confirming decreased use of cocaine among participants who received dexamfetamine. Adverse events The distribution of adverse events was as follows: dexamfetamine group 74% placebo group 46% According to the researchers, most side effects reported by dexamfetamine users resolved before the end of the study. Problems with sleep were the most common adverse event reported, distributed as follows: dexamfetamine group 34% placebo group 9%
3 The researchers did not find any serious side effects among participants who used dexamfetamine. Points to consider The present study took place in a supervised setting that required participants to visit a clinic daily. According to the researchers, this setting allowed clinic staff to motivate [participants] and intensely monitor potential side effects. Such a setting allowed the optimization of adherence. The duration of the study was short, just 12 weeks. Given that many participants had been taking street drugs for years, it is unreasonable to expect that a short intervention would have resulted in the cessation of cocaine use. However, the study provides encouraging news for researchers who work in the field of addiction and the rationale for a longer and larger study. Future research needs According to Swiss addiction specialists who have reviewed the Dutch study, there is a need for at least the following: confirmation of the study s findings in other populations, including younger people and women studies that help drug users with adherence to dexamfetamine who do not have the intense daily support received in the Dutch study exploring the safety of higher doses of dexamfetamine in cocaine dependency a combination of dexamfetamine with other potential anti-addiction agents to prolong periods off cocaine In a separate report, Canadian addiction researchers have called for a rigorous research programme to explore the potential effect of cannabinoids (compounds found in marijuana) in people who use crack cocaine. They note that small observational studies from several countries reported that marijuana has been taken by drug users to help alleviate the harmful effects of crack cocaine including paranoia, weight loss, craving, aggression and anxiety. Furthermore, in at least one of these reports, some crack cocaine users were able to overcome their addiction because of marijuana. Bear in mind According to Boston University addiction specialists and physicians Christine Pace and Jeffrey Samet: Studies suggest that [a person s genes] may contribute as much as 40% to 60% of an individual s risk for addiction. Environmental factors, particularly in childhood or adolescence, are also important, including age of first exposure to alcohol or drugs and adverse childhood experiences. Finally, substance use disorders are commonly associated with psychiatric comorbidities, including depression, anxiety and bipolar disorder. These conditions may contribute to an individual s vulnerability to addiction; in addition, anxiety and depressive symptoms may be a consequence of long-term substance use. Given all of these factors, a combination of approaches to help people deal with addiction is necessary. Such approaches should try to address the issues some of which are mentioned in the preceding paragraph that underlie and drive addiction. Resources Pre-fix: A guide for people with Hep C or HIV who inject drugs Prevention & Harm Reduction from Hepatitis C: An In-Depth Guide Best Practice Recommendations for Canadian Harm Reduction Programs REFERENCES: Sean R. Hosein 1. DeBeck K, Kerr T, Li K, et al. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ Oct 27;181(9):585-9.
4 2. Celentano D, Sherman SG. The changing landscape of crack cocaine use and HIV infection. CMAJ Oct 27;181(9): Nuijten M, Blanken P, van de Wetering B, et al. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet. 2016; in press. 4. Dürsteler KM, Vogel M. Effective drug therapy for cocaine dependence: a milestone. Lancet. 2016; in press. 5. Mooney ME, Herin DV, Specker S, et al. Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence Aug 1;153: Pace CA, Samet JH. Substance use disorders. Annals of Internal Medicine Apr 5;164(7):ITC49-ITC Fischer B, Blanken P, Da Silveira D, et al. Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies. International Journal on Drug Policy Apr;26(4): Nuijten M, Blanken P, van den Brink W, et al. Modafinil in the treatment of crack-cocaine dependence in the Netherlands: Results of an open-label randomised controlled feasibility trial. Journal of Psychopharmacology Jun;29(6): Glaser G. For Mark Willenbring, substance abuse treatment begins with research. New York Times. 22 February, Available at: Fischer B, Kuganesan S, Gallassi A, et al. Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. International Journal on Drug Policy Dec;26(12): Singh M, Keer D, Klimas J, et al. Topiramate for cocaine dependence: A systematic review and meta-analysis of randomized controlled trials. Addiction. 2016; in press. 12. Uhlmann S, Milloy MJ, Ahamad K, et al. Factors associated with willingness to participate in a pharmacologic addiction treatment clinical trial among people who use drugs. American Journal on Addictions Jun;24(4):
5 Produced By: 555 Richmond Street West, Suite 505, Box 1104 Toronto, Ontario M5V 3B1 Canada Phone: Toll-free: Fax: Charitable registration number: RR Disclaimer Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question. CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature. CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders. Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs. Permission to Reproduce This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at CATIE Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada. Available online at:
From Safer Sex Guide. Using condoms
From Safer Sex Guide Using condoms Click to enlarge Using condoms correctly and consistently can signifiantly reduce your chances of passing or getting HIV and other STIs. There are two types of condoms
More informationLong-acting drugs for HIV
From TreatmentUpdate 222 Long-acting drugs for HIV Long-acting formulations of two anti-hiv drugs are being tested in clinical trials: cabotegravir an experimental integrase inhibitor made available in
More informationThe debut of velpatasvir for hepatitis C
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The debut of velpatasvir for hepatitis C 23 November 2015 Hepatitis C virus (HCV) can be grouped into six major strains, or genotypes,
More informationHepatitis C treatment program improves access to housing, income and healthcare
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Hepatitis C treatment program improves access to housing, income and healthcare 13 July 2015 Despite high rates of hepatitis C virus (HCV)
More informationPatient navigators for hepatitis C patients found useful in New York City
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Patient navigators for hepatitis C patients found useful in New York City 4 January 2017 Hepatitis C virus (HCV) infects and injures the
More informationNorthern Alberta preventing HIV transmission to babies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Northern Alberta preventing HIV transmission to babies 25 June 2009 Since 1996 the widespread availability of combination therapy for HIV
More informationViral infections Hep C and HIV linked to hip fractures
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Viral infections Hep C and HIV linked to hip fractures 22 November 2012 Infection with hepatitis C virus (HCV) and HIV causes inflammation,
More informationUnderstanding risk by sex act
From Safer Sex Guide Understanding risk by sex act Kissing (with tongue) Chlamydia Avoid kissing if you or your partners have sores on the lips or mouth, or if one of you has an active oral infection (such
More informationExploring the risks of liver cancer after successful treatment for hepatitis C virus
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring the risks of liver cancer after successful treatment for hepatitis C virus 11 June 2013 In Canada and other high-income countries,
More informationDetailed results from the START study
From TreatmentUpdate 210 Detailed results from the START study Researchers in 35 countries across all continents collaborated to recruit 4,685 HIV-positive adults who were in good health for START. Upon
More informationDoravirine vs. darunavir
From TreatmentUpdate 220 Doravirine vs. darunavir Doravirine is an experimental non-nuke that is undergoing phase III clinical trials. It is designed to be effective against most strains of HIV that are
More informationA study about switching from TDF to TAF
From TreatmentUpdate 211 A study about switching from TDF to TAF Researchers enrolled HIV-positive participants who were taking regimens containing TDF (tenofovir disoproxil fumarate), the original formulation
More informationHow are testing technologies used to diagnose HIV infection?
HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including where the test is conducted,
More informationStudy finds PEP not 100% effective in preventing HIV infection
From TreatmentUpdate 152 Study finds PEP not 100% effective in preventing HIV infection Some doctors and nurses who care for PHAs may sustain needle-stick injuries. This raises the possibility that they
More informationNorwegian HIV vaccine Very modest results seen in recent clinical trial
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Norwegian HIV vaccine Very modest results seen in recent clinical trial 21 February 2012 Although HIV infection can be treated with combination
More informationThe epidemiology of HIV in Canada
FACTSHEET The epidemiology of HIV in Canada This fact sheet provides a snapshot of the HIV epidemic in Canada. It is one of a series of fact sheets on the epidemiology of HIV and hepatitis C in Canada.
More informationHere are some of the steps (greatly simplified) and gaps that can occur in the HIV Treatment Cascade:
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Alberta Reducing deaths by strengthening the HIV Treatment Cascade 20 May 2014 In Canada and other high-income countries, deaths from AIDS-related
More informationIs there a link between niacin and stroke?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Is there a link between niacin and stroke? 7 July 2011 A large American-Canadian study called Aim-High was halted 18 months ahead of schedule.
More informationThe epidemiology of hepatitis C in Canada
The epidemiology of hepatitis C in Canada FACT SHEET Published 2017 This fact sheet provides a snapshot of the hepatitis C epidemic in Canada. It is one of a series of fact sheets providing epidemiological
More informationLimiting the spread of hepatitis C virus with Treatment as Prevention (TasP)
From TreatmentUpdate 197 Limiting the spread of hepatitis C virus with Treatment as Prevention (TasP) The idea of Treatment as Prevention, or TasP, has been proposed and is being implemented in some regions
More informationPost-exposure prophylaxis (PEP)
Post-exposure prophylaxis (PEP) Summary Post-exposure prophylaxis, or PEP, is a way to help prevent the transmission of HIV in an HIV-negative person who may have been recently exposed to HIV. It involves
More informationHep C treatment can cure a person from Hep C. However, a person could get infected again.
Sofosbuvir (Sovaldi) Summary Sofosbuvir is a medication used to treat Hep C. It is used in combination with other medications to cure people of the Hep C virus. Sofosbuvir is taken at a dose of 400 mg
More informationHIV testing technologies
HIV testing technologies HIV testing technologies are used to determine if a person has HIV. Several types of HIV testing technologies are used in Canada. These tests differ in several ways, including
More informationCan mirtazapine assist recovery from crystal meth addiction?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can mirtazapine assist recovery from crystal meth addiction? 20 December 2011 Stimulants such as amphetamine and its more potent form,
More informationKey messages on hepatitis A for clients are available at the end of this fact sheet.
Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is transmitted
More informationHIV and the immune system linked to heart disease in women
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. HIV and the immune system linked to heart disease in women 26 September 2013 The widespread availability of potent combination anti-hiv
More informationHepatitis A FACTSHEET. Summary. What is hepatitis A?
FACTSHEET Hepatitis A Summary Hepatitis A is an infection caused by a virus that can be sexually transmitted. Infection with hepatitis A results in inflammation of the liver (hepatitis). Hepatitis A is
More informationStudy explores risk for shingles in the current era
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study explores risk for shingles in the current era 19 February 2015 Infection with VZV (varicella zoster virus), a member of the herpes
More informationCan metformin also protect arteries?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Can metformin also protect arteries? 8 December 2011 Reports suggest that cardiovascular disease is becoming common among HIV-positive
More informationDoes tenofovir (TDF) cause liver injury?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does tenofovir (TDF) cause liver injury? 10 February 2016 Tenofovir is an important antiviral drug used to treat HIV and hepatitis B virus
More informationStarting points. living with HIV
Starting points living with HIV Have you found out you have HIV and are trying to get your bearings? We can help you with the basics of living with HIV. Here s what you ll read about in this booklet: What
More informationIncreased risk for dialysis found with HIV infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Increased risk for dialysis found with HIV infection 12 September 2013 In high-income countries such as Canada, Australia and the U.S.
More informationHepatitis C Basics. Michael Bailey Director of Programming, CATIE. Mary Choy Regional Health Education Coordinator, CATIE
Hepatitis C Basics Michael Bailey Director of Programming, CATIE Mary Choy Regional Health Education Coordinator, CATIE CATIE Our History Learning Objectives 1) To learn about the basics of hepatitis C
More informationTHE POWER OF UNDETECTABLE. What you need to know about HIV treatment as prevention
THE POWER OF UNDETECTABLE What you need to know about HIV treatment as prevention CONTENTS 3 Treatment as prevention First, a few basics: What is an undetectable viral load? How do I know if I m undetectable?
More informationAmerican Academy of Pediatrics issues statement on infant feeding and HIV transmission
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. American Academy of Pediatrics issues statement on infant feeding and HIV transmission 7 February 2013 The widespread availability of potent
More informationCrystal meth interviews reveal its impact on HIV positive men
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Crystal meth interviews reveal its impact on HIV positive men 15 April 2009 Crystal meth, also known as ice or Tina, is a form of the stimulant
More informationDoes syphilis affect HIV in the brain?
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Does syphilis affect HIV in the brain? 1 February 2011 Outbreaks of sexually transmitted infections (STIs) are occurring in Canada and
More informationPre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
More informationIt is a good idea for anyone having sex to get tested regularly and treated for STIs if necessary.
FACTSHEET Sexually Transmitted Infections and HIV Transmission This is one of a series of fact sheets about the biology of HIV transmission. The fact sheets review specific biological factors that make
More informationSuperbug increasing among HIV positive people
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Superbug increasing among HIV positive people 24 September 2007 Bacteria are a common source of problems, causing a variety of infections,
More informationThe Patient as Partner
From The Positive Side, Summer 2018 The Patient as Partner The idea that a person should be an active participant, not just a recipient, of their own healthcare has deep roots. Feminists, people living
More informationProgramming Connection
The H.E.R. Pregnancy Program Programming Connection Case Study Organization: Streetworks Region: Edmonton, Alberta Prepared: 2018 Quick Facts Population Street involved, Women Date Started 2011 Region
More informationDaclatasvir (Daklinza)
Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in Canada for
More informationRaltegravir (Isentress)
Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Raltegravir is generally well tolerated. Common side effects include diarrhea, nausea and headache;
More informationHarvoni (ledipasvir + sofosbuvir)
Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with all genotypes of the hepatitis C virus. Harvoni is a combination of
More informationHepatitis C virus some background information
From TreatmentUpdate 167 Hepatitis C virus some background information Hepatitis C virus (HCV) is spread by exposure to infected blood. The following behaviours, which can expose a person to infected blood,
More informationQuad (Stribild) Safety and effectiveness issues in depth
From TreatmentUpdate 191 Quad (Stribild) Safety and effectiveness issues in depth The FDA reviewed health-related information collected from 1,408 HIV-positive people who participated in two pivotal clinical
More informationHarvoni (ledipasvir + sofosbuvir)
FACTSHEET Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with genotype 1 hepatitis C virus. Harvoni is a combination of
More informationDaclatasvir (Daklinza)
FACTSHEET Daclatasvir (Daklinza) Summary Daclatasvir (Daklinza) is a medication used to treat hepatitis C. It is taken with sofosbuvir (Sovaldi) and sometimes ribavirin. This combination is approved in
More information3TC (lamivudine, Epivir)
3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes few side
More informationWill de-simplification of HIV treatment become common in highincome
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Will de-simplification of HIV treatment become common in highincome countries? 13 February 2018 As more people start HIV treatment, researchers
More informationIMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C
IMPORTANT THINGS TO KNOW WHEN YOU HAVE HEPATITIS C GETTING STARTED: Important things to know when you have hepatitis C If you just found out that you have hepatitis C, you may have a lot of questions.
More informationExciting results in monkeys lead to a clinical trial in humans
From TreatmentUpdate 219 Exciting results in monkeys lead to a clinical trial in humans A close relative of HIV called SIV (simian immunodeficiency virus) causes an AIDS-like disease in susceptible monkeys.
More informationSafe Babies Foster Parent Training Program
Safe Babies Foster Parent Training Program Module 1: Introduction to the Safe Babies Program 1 Begin the process of group participation Learning outcomes Understand the purpose and origins of the Safe
More informationSchizophrenia and HIV Study underscores serious issues associated with dual diagnoses
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Schizophrenia and HIV Study underscores serious issues associated with dual diagnoses 15 July 2015 Several studies have found that some
More informationExploring risks for MRSA infection A tale of two studies
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Exploring risks for MRSA infection A tale of two studies 2 March 2012 A group of bacteria called S. aureus (Staphylococcus aureus ) are
More informationI ANTI-HIV AGENTS. Contents I ANTI-HIV AGENTS II COMPLICATIONS AND SIDE EFFECTS. A. Raltegravir vs. efavirenz four. years later
TreatmentUpdate 179 Vol. 22, No. 4 May/June 2010 ISSN 11817187 Available on the World Wide Web at www.catie.ca/tu.nsf Contents I ANTI-HIV AGENTS A. Raltegravir vs. efavirenz four years later 1 B. Raltegravir
More informationRibavirin (Ibavyr, Moderiba)
Ribavirin (Ibavyr, Moderiba) Summary Ribavirin is a medication used to treat hepatitis C. It is used in combination with other medications to cure people of the hepatitis C virus. Ribavirin is taken orally
More informationPOLICY AND GUIDANCE FOR MANAGERS ON STAFF SUBSTANCE MISUSE
POLICY AND GUIDANCE FOR MANAGERS ON STAFF SUBSTANCE MISUSE HEALTH & SAFETY UNIT AUTUMN 2012 CONTENTS 1 INTRODUCTION... ERROR! BOOKMARK NOT DEFINED. 2 AIM... ERROR! BOOKMARK NOT DEFINED. 3 APPLICATION...
More informationLymphoma FACTSHEET. Summary. About the lymphatic system. Who is at risk for lymphoma? What is lymphoma?
FACTSHEET Lymphoma Summary Lymphoma is a cancer that affects a part of the immune system called the lymphatic system. Like any cancer, the earlier lymphoma is diagnosed, the easier it is to treat. In general,
More informationThe HIV testing process
FACTSHEET The HIV testing process Summary There are a few steps that a person will take in the HIV testing process. To access an HIV test, people can request a test or may be offered a test. There are
More information3TC (lamivudine, Epivir)
FACTSHEET 3TC (lamivudine, Epivir) Summary 3TC is a type of antiretroviral drug called a nucleoside analogue (or nuke ). 3TC can cause nausea, headache, diarrhea, vomiting and weakness; however, it causes
More informationMG an emerging sexually transmitted infection
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. MG an emerging sexually transmitted infection 9 October 2013 The bacterium Mycoplasma genitalium (MG) is sexually transmitted and can cause
More informationDoes the Use of Oral Amphetamines Reduce Cocaine Use in Cocaine-Dependent Individuals?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Does the Use of Oral Amphetamines Reduce
More informationTri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary
Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent
More informationNOW CANADA SOCIETY TUTT STREET KELOWNA, BC V1Y 8Z5 TELEPHONE (250) FAX (250)
NOW CANADA SOCIETY 2970 TUTT STREET KELOWNA, BC V1Y 8Z5 TELEPHONE (250) 763-3876 FAX (250) 868-3876 EMAIL support@nowcanada.ca RESIDENTIAL / DAY PROGRAM REFERRAL PACKAGE THE NOW CANADA SOCIETY MISSION
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationTRENDS IN SUBSTANCE USE AND ASSOCIATED HEALTH PROBLEMS
Fact Sheet N 127 August 1996 TRENDS IN SUBSTANCE USE AND ASSOCIATED HEALTH PROBLEMS Psychoactive substance use is an increasing public health concern. Problems associated with this use cover a broad spectrum
More informationAsk the Experts: Managing Lipid Levels
From The Positive Side, Winter 2013 Ask the Experts: Managing Lipid Levels My doctor said that my lipid levels are cause for concern. Any do s and don ts you can share? JB, Brandon, Manitoba Interviews
More informationSFHAB2 - SQA Unit Code HG0T 04 Support individuals who misuse substances
Overview For this standard you need to support individuals who misuse substances by enabling them to adopt safe practices, providing care and support following an episode of substance use and supporting
More informationThe science of the mind: investigating mental health Treating addiction
The science of the mind: investigating mental health Treating addiction : is a Consultant Addiction Psychiatrist. She works in a drug and alcohol clinic which treats clients from an area of London with
More informationThe elusive AIDS vaccine
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. The elusive AIDS vaccine 4 March 2008 In the 25 years since HIV was discovered, researchers have made many strides in the fight against
More informationHPV, Cervical Dysplasia and Cancer
FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and
More informationHarm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD
Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD Objectives Provide an overview of harm reduction by defining shared language and key terms. Collaboratively
More informationDescovy FACTSHEET. Summary. What is Descovy? How does Descovy work?
FACTSHEET Descovy Summary Descovy is the name given to a pill containing the following two anti- HIV drugs: TAF (tenofovir alafenamide) and FTC (emtricitabine). Descovy comes in two, colour-coded strengths
More informationTorkin Manes LegalPoint
LegalPoint JULY 2017 Marijuana and the Canadian Workplace The possession, use and sale of marijuana in Canada presently remains unlawful under the Controlled Drugs and Substances Act, but its use for medical
More informationRibavirin (Copegus, Ibavyr, Moderiba)
FACTSHEET Ribavirin (Copegus, Ibavyr, Moderiba) Summary Ribavirin is a medication used to treat hepatitis C. It is used in combination with other medications to cure people of the hepatitis C virus. Ribavirin
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationMargot Kuo, Despina Tzemis, Ellison Richmond, Jane Buxton. CPHA 2012 June 12, 2012 Edmonton, AB
Margot Kuo, Despina Tzemis, Ellison Richmond, Jane Buxton CPHA 2012 June 12, 2012 Edmonton, AB Risks of smoking crack Risks of smoking crack Risk factor for HIV among people who inject (DeBeck et al. 2008)
More informationHIV treatment and an undetectable viral load to prevent HIV transmission
HIV treatment and an undetectable viral load to prevent HIV transmission FACT SHEET Published 2018 CONTACT US Summary It is now well known that the use of HIV treatment not only improves the health of
More informationCigarettes and Other Nicotine Products
Cigarettes and Other Nicotine Products Nicotine is one of the most heavily used addictive drugs in the United States. In 2002, 30 percent of the U.S. population 12 and older 71.5 million people used tobacco
More information- and. IN THE MATTER OF: The Medical Act, R.S.N.S , c and SETTLEMENT AGREEMENT
PROVINCE OF NOVA SCOTIA ) COUNTY OF HALIFAX ) IN THE MATTER OF: The Canada Evidence Act - and IN THE MATTER OF: The Medical Act, R.S.N.S. 1995-96, c.10 - and IN THE MATTER OF: Dr. David Russell SETTLEMENT
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Drug Misuse: opiate detoxification of drug misusers in the community, hospital and prison. 1.1 Short title Drug misuse detoxification
More informationEMERGING ISSUES IN SMOKING CESSATION
EMERGING ISSUES IN SMOKING CESSATION Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe, CM, MD University
More informationVivitrol/Suboxone. Comparison Study Summary
Vivitrol/Suboxone Comparison Study Summary Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., & King, J. (2017). Comparative effectiveness of extended-release naltrexone versus
More informationThe forgotten group: a new HIV outbreak amongst people who inject drugs. Patricia Anderson Lead CNS BBV Brownlee Centre
The forgotten group: a new HIV outbreak amongst people who inject drugs Patricia Anderson Lead CNS BBV Brownlee Centre No conflicts to declare Potted History 1981 Modern wave of drug misuse Glasgow soared
More informationRaltegravir (Isentress)
FACTSHEET Raltegravir (Isentress) Summary Raltegravir is a type of anti-hiv drug called an integrase inhibitor. Common side effects of raltegravir include diarrhea, nausea and headache; these are usually
More informationH5VL 04 (SFH AB2) Support Individuals Who are Substance Users
H5VL 04 (SFH AB2) Support Individuals Who are Substance Users Overview For this standard you need to support individuals who are substance users by enabling them to adopt safe practices, providing care
More informationFDAP Drug & Alcohol Professional Certification Workplace Assessment
DANOS AB2 Support individuals who are substance users This unit is about supporting individuals who are substance users by enabling them to adopt safe practices, providing care and support following an
More informationHepatitis C Strategy. About us. What is hepatitis C?
Hepatitis C Strategy About us We support people to take control of their lives and make positive changes. For fifty years we have made a difference to people who want to change their relationship with
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationOpioids Are Seniors at Risk? (April 26, 2018)
Opioids Are Seniors at Risk? (April 26, 2018) Seniors are living longer and, with age, they become vulnerable to health challenges and the pain that may accompany them. Thus, it is perhaps not surprising
More informationAn Evolving Perspective on Smoking Cessation Therapies
An Evolving Perspective on Smoking Cessation Therapies Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe,
More informationAnalysis of Greater Glasgow & Clyde IEP Data John Campbell
Analysis of Greater Glasgow & Clyde IEP Data 2-2 John Campbell Contents Overview of the programme... 3 About this report... 4 Key points... 4 Drugs injected... 5 Drugs injected at transaction by unique
More informationMedication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.
Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation
More informationDual Diagnosis. Themed Review Report 2006/07 SHA Regional Reports East Midlands
Dual Diagnosis Themed Review Report 2006/07 SHA Regional Reports East Midlands Contents Foreword 1 Introduction 2 Recommendations 2 Themed Review 06/07 data 3 Additional information 13 Weighted population
More informationHistorical Perspectives
Why Harm Reduction? 1 Rochelle Head-Dunham, MD FAPA Executive Director and Medical Director Metropolitan Human Services District Clinical Associate Professor of Psychiatry LSU and Tulane Historical Perspectives
More informationWomen s Experiences of Recovery from Substance Misuse
Women s Experiences of Recovery from Substance Misuse A review of women s only group therapy I have got my life back. The group provided me with a safe haven. It was for the first time in years that I
More informationShould buprenorphine be covered for maintenance treatment in opioid dependent persons?
Prepared by: Silvia Pregno May 13,2012 Patients: people with opioid dependence Should buprenorphine be covered for maintenance treatment in opioid dependent persons? Intervention: buprenorphine Comparison:
More informationTuberculosis FACT SHEET. Summary. What is TB?
Tuberculosis Summary Tuberculosis (TB) is caused by bacteria called Mycobacterium tuberculosis complex and usually affects the lungs. However, among people co-infected with TB and HIV, parts of the body
More information